|
JP4173538B2
(ja)
*
|
1995-02-24 |
2008-10-29 |
スチュアート エル ウェグ |
痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
CA2529857A1
(en)
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US20040248964A1
(en)
*
|
2002-11-18 |
2004-12-09 |
Crooks Peter A. |
Analgesic uses of norketamine and ketamine/norketamine prodrugs
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
CA2516619A1
(en)
|
2003-02-26 |
2004-09-10 |
Johns Hopkins University |
Glutamate transport modulatory compounds and methods
|
|
US20050038062A1
(en)
|
2003-04-14 |
2005-02-17 |
Burns Lindsay H. |
Methods and materials for the treatment of pain comprising opioid antagonists
|
|
JP2007533725A
(ja)
|
2004-04-20 |
2007-11-22 |
ファイザー・インク |
Ｃｒｔｈ２受容体アンタゴニストを用いたニューロパシー性疼痛処置方法
|
|
EP1799264A2
(en)
|
2004-10-08 |
2007-06-27 |
Neuromolecular Pharmaceuticals Inc |
Methods and compositions for treating migraine pain
|
|
US20080096872A1
(en)
|
2004-12-22 |
2008-04-24 |
Friedman Robert S |
Composition for Treatment of Pain Specification
|
|
CA2599662A1
(en)
|
2005-03-01 |
2006-09-08 |
Pfizer Limited |
Use of pde7 inhibitors for the treatment of neuropathic pain
|
|
EP1861003A1
(en)
|
2005-03-04 |
2007-12-05 |
Mentis Cura ehf. |
A method and a system for assessing neurological conditions
|
|
MX2007012374A
(es)
|
2005-04-06 |
2008-02-22 |
Adamas Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
JP2009520040A
(ja)
|
2005-12-19 |
2009-05-21 |
ファーマイン コーポレーション |
治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
|
|
CN101466364A
(zh)
*
|
2006-03-22 |
2009-06-24 |
纽约大学西奈山医学院 |
鼻内施用氯胺酮治疗抑郁症
|
|
BRPI0711872A2
(pt)
|
2006-05-22 |
2011-12-06 |
Vanda Pharmaceuticals Inc |
tratamento para distúrbios depressivos
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
CA2677219A1
(en)
|
2007-02-01 |
2009-01-29 |
Alan I. Green |
Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
SI2125698T1
(sl)
|
2007-03-15 |
2016-12-30 |
Auspex Pharmaceuticals, Inc. |
Devterirani d9-venlafaksin
|
|
US20080280886A1
(en)
|
2007-05-08 |
2008-11-13 |
Auspex Pharmaceuticals, Inc. |
Substituted ureas
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
US20100316678A1
(en)
|
2007-06-28 |
2010-12-16 |
Cnsbio Pty Ltd. |
Combination methods and compositions for treatment of neuropathic pain
|
|
WO2009015389A2
(en)
|
2007-07-26 |
2009-01-29 |
Entra Pharmaceuticals Inc. |
Skin-patch pump comprising a changing-volume electrochemical actuator
|
|
EP2184986A4
(en)
|
2007-08-06 |
2010-12-15 |
Trinity Lab Inc |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
|
|
WO2009039460A2
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
Co-administration of pimavanserin with other agents
|
|
JP2011507800A
(ja)
|
2007-12-26 |
2011-03-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
DK2493457T3
(en)
|
2009-10-30 |
2017-10-02 |
Ix Biopharma Ltd |
QUICK-SOLVING SOLID DOSAGE FORM
|
|
CN107468211A
(zh)
|
2010-01-18 |
2017-12-15 |
艾欧敏达有限公司 |
用于分析神经生理学数据的方法和系统以及评估系统
|
|
US9073819B2
(en)
|
2011-06-30 |
2015-07-07 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
EP2791352A1
(en)
|
2011-12-14 |
2014-10-22 |
Astrazeneca AB |
Gabr-a2 diagnostic
|
|
CN104519878A
(zh)
|
2012-03-12 |
2015-04-15 |
詹森药业有限公司 |
用于治疗顽固性或难治性抑郁症的艾氯胺酮
|
|
WO2013149102A1
(en)
|
2012-03-30 |
2013-10-03 |
The General Hospital Corporation |
Compositions comprising scopolamine and ketamine in the treatment of depression
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
WO2014020155A1
(en)
|
2012-08-02 |
2014-02-06 |
Clinpharm Reform Gmbh |
Oral transmucosal adminstration forms of s-ketamine
|
|
CN104902883A
(zh)
|
2012-08-23 |
2015-09-09 |
斯图亚特·L·韦格 |
抗焦虑组合物、制剂及使用方法
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
CA2895129C
(en)
|
2012-12-20 |
2022-07-05 |
Sanford-Burnham Medical Research Institute |
Quinazoline neurotensin receptor 1 agonists and uses thereof
|
|
SG10201802104QA
(en)
|
2013-03-15 |
2018-05-30 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
KR20230156807A
(ko)
|
2013-03-15 |
2023-11-14 |
얀센 파마슈티카 엔브이 |
S-케타민 하이드로클로라이드의 약제학적 조성물
|
|
CA2907566C
(en)
*
|
2013-04-01 |
2023-08-22 |
Pulmatrix, Inc. |
Tiotropium dry powders
|
|
WO2015031410A1
(en)
|
2013-08-26 |
2015-03-05 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
DK3043785T3
(da)
|
2013-09-13 |
2021-11-15 |
Univ Chiba Nat Univ Corp |
Anvendelse af r-ketamin og salt deraf som lægemidler
|
|
EP3094312B1
(en)
|
2014-01-14 |
2019-03-13 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
ES2935800T3
(es)
|
2014-04-17 |
2023-03-10 |
Ketabon Gmbh |
Forma de dosificación oral de ketamina
|
|
RU2721948C2
(ru)
|
2014-05-06 |
2020-05-25 |
Нортвестерн Юниверсити |
Комбинации соединений, модулирующих nmda-рецептор
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
US10098854B2
(en)
|
2014-08-13 |
2018-10-16 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
|
KR20170054470A
(ko)
|
2014-09-15 |
2017-05-17 |
얀센 파마슈티카 엔.브이. |
VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
|
|
BR112017006842A2
(pt)
*
|
2014-10-07 |
2017-12-12 |
Lam Therapeutics Inc |
formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
|
|
SI3215147T1
(sl)
|
2014-11-04 |
2024-05-31 |
Acadia Pharmaceuticals Inc. |
Nevroatenuacijske spojine norketamina in postopki
|
|
CA2970065A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
WO2016109427A1
(en)
|
2014-12-31 |
2016-07-07 |
Icahn School Of Medicine At Mount Sinai |
Method of maintaining the anti-depressant effect of ketamine with lithium
|
|
WO2016112467A1
(en)
|
2015-01-15 |
2016-07-21 |
Centre For Addiction And Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
*
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
AU2016274988A1
(en)
|
2015-06-12 |
2017-12-21 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
EP3297620A4
(en)
|
2015-06-27 |
2019-01-09 |
Shenox Pharmaceuticals, LLC |
TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
AU2016340080A1
(en)
|
2015-10-16 |
2018-05-10 |
Northwestern University |
Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
US11110070B2
(en)
|
2015-11-17 |
2021-09-07 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
CN109475514A
(zh)
|
2016-03-25 |
2019-03-15 |
美国政府健康及人类服务部 |
使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法
|
|
IL263153B2
(en)
|
2016-05-25 |
2023-09-01 |
National Health Res Inst |
Method and composition to lower the psychotic and addictive disorder of ketamine
|
|
US10266582B2
(en)
|
2016-07-28 |
2019-04-23 |
Regeneron Pharmaceuticals, Inc. |
GPR156 variants and uses thereof
|
|
CA3030359A1
(en)
|
2016-08-05 |
2018-02-08 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal pharmaceutical powder compositions
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
WO2018079693A1
(ja)
|
2016-10-27 |
2018-05-03 |
国立大学法人 千葉大学 |
（ｓ）－ノルケタミンおよびその塩の医薬品としての応用
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
US20200030251A1
(en)
|
2017-04-20 |
2020-01-30 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
WO2018209341A1
(en)
|
2017-05-12 |
2018-11-15 |
Indiana University Research And Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
AU2018274765A1
(en)
|
2017-05-25 |
2020-01-23 |
Glytech Llc. |
Formulations for treatment of post-traumatic stress disorder
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
EP3641742A2
(en)
|
2017-06-23 |
2020-04-29 |
Develco Pharma Schweiz AG |
Hydroxynorketamine for the use in the treatment of depression
|
|
EP3668490A4
(en)
|
2017-08-20 |
2021-06-09 |
Formulex Pharma Innovations Ltd. |
Dry powder compositions for intranasal delivery
|
|
US20210315840A1
(en)
|
2017-09-25 |
2021-10-14 |
Small Pharma Ltd |
Solid oral dosage forms of ketamine derivatives
|
|
JP7265990B2
(ja)
|
2017-09-27 |
2023-04-27 |
国立大学法人千葉大学 |
神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
US12090123B2
(en)
|
2017-10-10 |
2024-09-17 |
Douglas Pharmaceuticals Ltd. |
Extended release pharmaceutical formulation
|
|
CA3079560A1
(en)
|
2017-10-19 |
2019-04-25 |
Eleusis Benefit Corporation, Pbc |
Methods and systems for enhancing safety of psychedelic drug therapies
|
|
US11491120B2
(en)
|
2017-11-09 |
2022-11-08 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
EP3710079A4
(en)
|
2017-11-14 |
2021-09-01 |
Bexson Biomedical, Inc. |
SYSTEMS, DEVICES, FORMULATIONS AND PROCEDURES FOR CONTROLLED INGREDIENT DELIVERY
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
CN112423789A
(zh)
|
2017-12-22 |
2021-02-26 |
詹森药业有限公司 |
用于治疗抑郁症的艾司氯胺酮
|
|
PL3505157T3
(pl)
|
2017-12-29 |
2022-04-11 |
Celon Pharma S.A. |
Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
|
|
WO2019137381A1
(en)
|
2018-01-10 |
2019-07-18 |
Xw Laboratories, Inc. |
Prodrugs of ketamine, compositions and uses thereof
|
|
AU2019223014B2
(en)
|
2018-02-21 |
2024-10-17 |
Orphai Therapeutics Inc. |
Combination therapy with apilimod and glutamatergic agents
|
|
MX2020009668A
(es)
|
2018-03-16 |
2021-01-08 |
Intra Cellular Therapies Inc |
Métodos novedosos.
|
|
EP3761970A4
(en)
|
2018-03-26 |
2022-06-08 |
Cellix Bio Private Limited |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
US11426367B2
(en)
|
2018-05-04 |
2022-08-30 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
CN118986932A
(zh)
|
2018-05-31 |
2024-11-22 |
昆士兰大学 |
核壳聚合物纳米颗粒及其制备方法和用途
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
MX2020014000A
(es)
|
2018-06-27 |
2021-06-15 |
Bioxcel Therapeutics Inc |
Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
|
|
AU2019293515B2
(en)
|
2018-06-27 |
2024-10-24 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
US12005142B2
(en)
|
2018-08-02 |
2024-06-11 |
Taiwan Liposome Co., Ltd. |
Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
WO2020041329A1
(en)
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
PL3628313T3
(pl)
*
|
2018-09-28 |
2025-06-23 |
Novohale Therapeutics, Llc |
Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
WO2020086673A1
(en)
|
2018-10-26 |
2020-04-30 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
EP3873447A1
(en)
|
2018-10-29 |
2021-09-08 |
Hadasit Medical Research Services and Development Ltd. |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
CN113395962A
(zh)
|
2018-11-21 |
2021-09-14 |
Certego治疗公司 |
加波沙朵用于降低自杀风险和快速缓解抑郁症
|
|
AU2020206826B2
(en)
|
2019-01-11 |
2024-05-02 |
Alar Pharmaceuticals Inc. |
Ketamine pamoate and use thereof
|
|
SG11202107978RA
(en)
|
2019-01-23 |
2021-08-30 |
Univ Michigan Regents |
Methods and system for the reconstruction of drug response and disease networks and uses thereof
|
|
WO2020168213A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
MX2021010683A
(es)
|
2019-03-05 |
2021-12-10 |
Janssen Pharmaceuticals Inc |
Esketamina para el tratamiento de la depresión.
|
|
WO2020181194A1
(en)
|
2019-03-07 |
2020-09-10 |
University Of Padova |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
US20220143147A1
(en)
|
2019-03-18 |
2022-05-12 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
WO2020212596A1
(en)
|
2019-04-17 |
2020-10-22 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system
|
|
US20220313650A1
(en)
|
2019-05-02 |
2022-10-06 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
WO2020225774A1
(en)
|
2019-05-07 |
2020-11-12 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
EP3976145B1
(en)
|
2019-05-31 |
2025-01-15 |
Celon Pharma S.A. |
An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
|
|
WO2020239243A1
(en)
|
2019-05-31 |
2020-12-03 |
Celon Pharma S.A. |
Electronically supervised administration of a pharmaceutical composition
|
|
EP3979995A4
(en)
|
2019-06-04 |
2023-07-26 |
ADNP Kids Research Foundation |
KETAMINE AND KETAMINE/NAP FOR THE TREATMENT OF ADNP SYNDROME AND RELATED NEUROLOGICAL CONDITIONS
|
|
WO2021026232A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
JP2022546456A
(ja)
|
2019-08-28 |
2022-11-04 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
US20220339123A1
(en)
|
2019-09-13 |
2022-10-27 |
Janssen Pharmaceuticals, Inc. |
Intranasal administration of esketamine
|
|
CA3156497A1
(en)
|
2019-10-02 |
2021-04-08 |
Praxis Precision Medicines, Inc. |
COMBINATIONS OF GABA-A RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND NMDA ANTAGONISTS, NMDA NEGATIVE ALLOSTERIC MODULATORS OR NMDA PARTIAL AGONISTS
|
|
WO2021074448A1
(en)
|
2019-10-18 |
2021-04-22 |
Institute Of Science And Technology Austria |
Stimulation of neuronal plasticity
|
|
WO2021087258A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
WO2021108801A2
(en)
|
2019-11-15 |
2021-06-03 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
WO2021101867A1
(en)
|
2019-11-18 |
2021-05-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same
|
|
AU2020386445A1
(en)
|
2019-11-19 |
2022-06-02 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
EP4076410B1
(en)
|
2019-12-20 |
2025-09-10 |
Alar Pharmaceuticals Inc. |
Long-acting injectable formulations of ketamine pamoate salts
|
|
WO2021137147A1
(en)
|
2019-12-30 |
2021-07-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
US12478592B2
(en)
|
2019-12-30 |
2025-11-25 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
|
CN115135317A
(zh)
|
2020-01-22 |
2022-09-30 |
西洛斯治疗有限公司 |
减少nmda拮抗剂的副作用
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
WO2021207349A1
(en)
|
2020-04-07 |
2021-10-14 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
JP2023526439A
(ja)
|
2020-05-20 |
2023-06-21 |
セルテゴ セラピューティクス インコーポレイテッド |
精神障害の処置のための環重水素化ガボキサドールおよびその使用
|
|
US20230210789A1
(en)
|
2020-06-02 |
2023-07-06 |
Ix Biopharma Limited |
Methods for treating major depressive disorder and treatment-resistant depression
|
|
WO2021255522A1
(en)
|
2020-06-19 |
2021-12-23 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
CA3191160A1
(en)
|
2020-08-18 |
2022-02-24 |
Oakwood Laboratories, Llc |
Microsphere formulations comprising ketamine and methods for making and using the same
|
|
WO2022081350A2
(en)
|
2020-09-30 |
2022-04-21 |
Duke University |
Methods for identification, stratification, and treatment of cns diseases
|
|
US20230404914A1
(en)
|
2020-11-09 |
2023-12-21 |
Lts Lohmann Thereapie-Systeme Ag |
Oral thin film
|
|
EP4247259A4
(en)
|
2020-11-18 |
2024-10-16 |
Indiana University Research and Technology Corporation |
METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, ADAPTATION TO EXISTING MEDICATIONS AND NEW MEDICATION USE METHODS AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
US11690811B2
(en)
|
2021-08-13 |
2023-07-04 |
XWPharma Ltd. |
Pharmaceutical compositions and oral dosage forms of ketamine derivatives
|
|
WO2023081109A1
(en)
|
2021-11-05 |
2023-05-11 |
Malcolm Thomas |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
US20240009145A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|